Meridian Bioscience, Inc. (NASDAQ:VIVO) announced a quarterly dividend on Wednesday, January 24th, NASDAQ reports. Shareholders of record on Monday, February 5th will be paid a dividend of 0.125 per share on Thursday, February 15th. This represents a $0.50 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date is Friday, February 2nd.
Shares of Meridian Bioscience (VIVO) opened at $16.10 on Friday. The stock has a market capitalization of $685.38, a P/E ratio of 31.57 and a beta of 0.90. The company has a current ratio of 5.85, a quick ratio of 4.04 and a debt-to-equity ratio of 0.30. Meridian Bioscience has a 12-month low of $12.05 and a 12-month high of $16.30.
Meridian Bioscience (NASDAQ:VIVO) last announced its earnings results on Thursday, January 25th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. The firm had revenue of $52.30 million during the quarter, compared to analysts’ expectations of $49.00 million. Meridian Bioscience had a return on equity of 17.09% and a net margin of 10.46%. The company’s revenue was up 11.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.15 earnings per share. equities analysts forecast that Meridian Bioscience will post 0.66 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Meridian Bioscience, Inc. (VIVO) Declares Quarterly Dividend of $0.13” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/28/meridian-bioscience-inc-vivo-declares-quarterly-dividend-of-0-13.html.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.